Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Open-label extension study of onartuzumab in solid tumors
2014-005438-69Phase 3Completed
- Sponsor
- Roche
- Start
- Apr 2015
- Modality
- Monoclonal Antibodies → Antibody-Based Therapeutics
- Countries
- 1
01
Overview
Phase 3, open-label trial of onartuzumab in Nonhematologic neoplasms and non-small cell lung cancer (NSCLC) (4 arms), sponsored by Roche. Started Apr 2015; status: completed.
02
Drugs
onartuzumab
03
Conditions
Nonhematologic neoplasmsnon-small cell lung cancer (NSCLC)
Beyond the preview
Go deeper on 2014-005438-69.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2014-005438-69.